Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Core Insights - Ardelyx, Inc. presented data on XPHOZAH at the American Society of Nephrology's Kidney Week, highlighting its effectiveness in real-world settings for patients with chronic kidney disease on dialysis [1][3] Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs [1][15] - The company has two commercial products approved in the United States: IBSRELA and XPHOZAH, with ongoing development of next-generation therapies [15][16] Product Information - XPHOZAH is the first phosphate absorption inhibitor approved by the FDA for reducing serum phosphorus in adults with chronic kidney disease on dialysis [2][14] - It is administered as a single tablet taken twice daily and works by blocking phosphate absorption in the gut [2][10] Clinical Study Results - The first real-world study of XPHOZAH showed that patients experienced an average reduction in serum phosphate of nearly 1 mg/dL, with 45.3% of participants achieving a reduction of ≥1 mg/dL [3][4] - A separate survey indicated that 63% of patients reported improved phosphate levels since starting tenapanor, with 69% feeling better about their phosphate control [4] Patient Experience - Positive patient experiences were reported, including improved bowel movements and lower pill burden, with 44% attributing improvements to better phosphate control [4] - Tenapanor also demonstrated effectiveness in improving bowel movements in patients with end-stage kidney disease and constipation [6][7] Economic Analysis - A cost-effectiveness analysis in Japan concluded that tenapanor is cost-effective for hemodialysis patients, meeting the threshold of five million Japanese Yen for willingness to pay [8]